U.S. Markets open in 5 hrs 30 mins

Rafarma Pharmaceuticals, Inc. (RAFA)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.1200+0.6750 (+46.71%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4450
Open1.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4400 - 2.2100
52 Week Range0.1780 - 2.9500
Volume179,708
Avg. Volume144,530
Market Cap177.798M
Beta (5Y Monthly)-0.75
PE Ratio (TTM)N/A
EPS (TTM)-0.0140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Rafarma Adds Prestigious New Board Chairman Ilia Shpurov
    GlobeNewswire

    Rafarma Adds Prestigious New Board Chairman Ilia Shpurov

    Rafarma Pharmaceuticals, Inc Mr. ShpurovLjubljana, Slovenia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma (http://kraspharma.ru) in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group technology park in 2004. It is now the largest technology park in Russia in terms of residents and size (4 square kilometers of land and 560,000 meters in building space). Mr. Shpurov is also Vice President of the International Congress of Industrialists and Entrepreneurs (http://www.ic-ie.com) . Mr. Shpurov brings unique experience to the board of directors and is a well-known businessman throughout Europe. His expertise in pharmaceutical growth will power Rafarma toward its goals of worldwide growth and profitability.Vladimir Dolgolenko CEO of Rafarma stated “we are very excited Mr. Shpurov has joined the board. His expertise, knowledge, reputation and resources will prove invaluable to the company in the coming months and years. We are extremely excited for the opportunities he brings to the company moving forward.”Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.For more information contact: RAFARMA (307) 429-2029Attachment * Rafarma Pharmaceuticals, Inc

  • GlobeNewswire

    Rafarma Conducts Strategy Conference in Thailand for University and Hospital Joint Venture

    Ljubljana, Slovenia, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that Mr. Anucha Pehtpeng, Rafarma’s Director of Thai Operations, represented the company along with leading research teams of from Mahidol University, Yala University and Siriraj Hospital. at a key conference in Bangkok from August 29 through 31. The main point of the conference was to discuss the future collaboration between Rafarma Pharmaceuticals and the above-mentioned institutions. Mr. Pehtpeng presented Rafarma’s research on the already-proven effects of cannabis-based anti-depression drugs. Mr. Pehtpeng had also presented the company’s advances in a new generation of anti-aging drugs. The conference concluded with Mr. Pehtpeng outlining the importance of the South-East Asian markets and all conference attendees agreed on the importance of joint research projects being commenced between Rafarma Pharmaceuticals and the above-mentioned institutions.Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.For more information contact: RAFARMA (307) 429-2029

  • GlobeNewswire

    Rafarma Establishes Thailand Corporate Entity For Merger and Expansion Projects

    Ljubljana, Slovenia, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. “OTC:(RAFA)” is pleased to announce that it has established a new corporate entity in Thailand. The entity is registered under the name of RAFARMA (THAILAND) CO., LTD. The Company intends to use the business entity for entering into new association agreements with Thai universities. New association agreements are currently under negotiations and are expected to cover research and joint projects in production of cannabis based products. Also, in the light of recent agreement with R. & D. BIOCOGENCY LABORATORIES GROUP, the Company will use the new entity to conduct clinical trials and license its new products in Thailand for future distribution in South-East Asian markets. For more information, contact:RAFARMA (307) 429-2029